Homo sapiens Protein: GBA
Summary
InnateDB Protein IDBP-103193.6
Last Modified 2014-10-13 [Report errors or provide feedback]
Gene Symbol GBA
Protein Name glucosidase, beta, acid
Synonyms GBA1; GCB; GLUC;
Species Homo sapiens
Ensembl Protein ENSP00000314508
InnateDB Gene IDBG-103191 (GBA)
Protein Structure
UniProt Annotation
Function
Subcellular Localization Lysosome membrane {ECO:0000269PubMed:17187079, ECO:0000269PubMed:17897319, ECO:0000269PubMed:18022370}; Peripheral membrane protein {ECO:0000269PubMed:17187079, ECO:0000269PubMed:17897319, ECO:0000269PubMed:18022370}; Lumenal side {ECO:0000269PubMed:17187079, ECO:0000269PubMed:17897319, ECO:0000269PubMed:18022370}. Note=Interaction with saposin-C promotes membrane association. Targeting to lysosomes occurs through an alternative MPR-independent mechanism via SCARB2.
Disease Associations Gaucher disease (GD) [MIM:230800]: A lysosomal storage disease due to deficient activity of beta-glucocerebrosidase and characterized by accumulation of glucosylceramide in the reticulo- endothelial system. Different clinical forms are recognized depending on the presence (neuronopathic forms) or absence of central nervous system involvement, severity and age of onset. {ECO:0000269PubMed:10352942, ECO:0000269PubMed:10360404, ECO:0000269PubMed:10447266, ECO:0000269PubMed:10744424, ECO:0000269PubMed:10796875, ECO:0000269PubMed:11933202, ECO:0000269PubMed:11992489, ECO:0000269PubMed:12204005, ECO:0000269PubMed:15292921, ECO:0000269PubMed:1972019, ECO:0000269PubMed:1974409, ECO:0000269PubMed:7627184, ECO:0000269PubMed:7627192, ECO:0000269PubMed:7916532, ECO:0000269PubMed:8076951, ECO:0000269PubMed:8112750, ECO:0000269PubMed:8294033, ECO:0000269PubMed:8432537, ECO:0000269PubMed:8790604, ECO:0000269PubMed:8829654, ECO:0000269PubMed:8829663, ECO:0000269PubMed:8937765, ECO:0000269PubMed:9061570, ECO:0000269PubMed:9153297, ECO:0000269PubMed:9182788, ECO:0000269PubMed:9217217, ECO:0000269PubMed:9279145, ECO:0000269PubMed:9516376, ECO:0000269PubMed:9554454, ECO:0000269PubMed:9554746, ECO:0000269PubMed:9650766, ECO:0000269PubMed:9683600}. Note=The disease is caused by mutations affecting the gene represented in this entry.Gaucher disease 1 (GD1) [MIM:230800]: A form of Gaucher disease characterized by hepatosplenomegaly with consequent anemia and thrombopenia, and bone involvement. The central nervous system is not involved. {ECO:0000269PubMed:10206680, ECO:0000269PubMed:10340647, ECO:0000269PubMed:15605411, ECO:0000269PubMed:8889591, ECO:0000269Ref.14}. Note=The disease is caused by mutations affecting the gene represented in this entry.Gaucher disease 2 (GD2) [MIM:230900]: The most severe form of Gaucher disease. It manifests soon after birth, with death generally occurring before patients reach two years of age. {ECO:0000269PubMed:9637431, ECO:0000269PubMed:9851895}. Note=The disease is caused by mutations affecting the gene represented in this entry.Gaucher disease 3 (GD3) [MIM:231000]: A subacute form of neuronopathic Gaucher disease. It has later onset and slower progression compared to the acute form of neuronopathic Gaucher disease 2. {ECO:0000269PubMed:8780099}. Note=The disease is caused by mutations affecting the gene represented in this entry.Gaucher disease 3C (GD3C) [MIM:231005]: A variant of subacute neuronopathic Gaucher disease 3 associated with cardiovascular calcifications. Note=The disease is caused by mutations affecting the gene represented in this entry.Gaucher disease perinatal lethal (GDPL) [MIM:608013]: Distinct form of Gaucher disease type 2, characterized by fetal onset. Hydrops fetalis, in utero fetal death and neonatal distress are prominent features. When hydrops is absent, neurologic involvement begins in the first week and leads to death within 3 months. Hepatosplenomegaly is a major sign, and is associated with ichthyosis, arthrogryposis, and facial dysmorphism. Note=The disease is caused by mutations affecting the gene represented in this entry.Note=Perinatal lethal Gaucher disease is associated with non-immune hydrops fetalis, a generalized edema of the fetus with fluid accumulation in the body cavities due to non-immune causes. Non-immune hydrops fetalis is not a diagnosis in itself but a symptom, a feature of many genetic disorders, and the end-stage of a wide variety of disorders.Parkinson disease (PARK) [MIM:168600]: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features. {ECO:0000269PubMed:12847165, ECO:0000269PubMed:16148263, ECO:0000269PubMed:19286695}. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry.
Tissue Specificity
Comments
Interactions
Number of Interactions This gene and/or its encoded proteins are associated with 17 experimentally validated interaction(s) in this database.
They are also associated with 2 interaction(s) predicted by orthology.
Experimentally validated
Total 17 [view]
Protein-Protein 17 [view]
Protein-DNA 0
Protein-RNA 0
DNA-DNA 0
RNA-RNA 0
DNA-RNA 0
Predicted by orthology
Total 2 [view]
Gene Ontology

Molecular Function
Accession GO Term
GO:0004348 glucosylceramidase activity
GO:0005102 receptor binding
GO:0005515 protein binding
Biological Process
GO:0005975 carbohydrate metabolic process
GO:0006665 sphingolipid metabolic process
GO:0006680 glucosylceramide catabolic process
GO:0006687 glycosphingolipid metabolic process
GO:0008219 cell death
GO:0009268 response to pH
GO:0023021 termination of signal transduction
GO:0032715 negative regulation of interleukin-6 production
GO:0033561 regulation of water loss via skin
GO:0033574 response to testosterone
GO:0035307 positive regulation of protein dephosphorylation
GO:0043407 negative regulation of MAP kinase activity
GO:0043589 skin morphogenesis
GO:0043627 response to estrogen
GO:0044281 small molecule metabolic process
GO:0046512 sphingosine biosynthetic process
GO:0046513 ceramide biosynthetic process
GO:0050728 negative regulation of inflammatory response
GO:0051384 response to glucocorticoid
GO:0071356 cellular response to tumor necrosis factor
GO:0097066 response to thyroid hormone
Cellular Component
GO:0005765 lysosomal membrane
GO:0043202 lysosomal lumen
GO:0070062 extracellular vesicular exosome
Protein Structure and Domains
PDB ID
InterPro IPR001139 Glycoside hydrolase, family 30
IPR017853 Glycoside hydrolase, superfamily
PFAM PF02055
PRINTS PR00843
PIRSF
SMART
TIGRFAMs
Post-translational Modifications
Modification
Cross-References
SwissProt P04062
PhosphoSite PhosphoSite-P04062
TrEMBL Q9UQU9
UniProt Splice Variant
Entrez Gene 2629
UniGene Hs.679157
RefSeq NP_001005742
HUGO HGNC:4177
OMIM 606463
CCDS CCDS1102
HPRD 06973
IMGT
EMBL AF023268 AK291911 AK298900 AK300829 AL713999 BC003356 D13286 D13287 J03059 K02920 M16328 M18916 M18917 M19285 M20248 M20282
GenPept AAA35873 AAA35874 AAA35875 AAA35876 AAA35877 AAA35878 AAA35879 AAA35880 AAC51820 AAC63056 AAH03356 BAA02545 BAA02546 BAF84600 BAH12898 BAH13357 CAI95090